Risk assessment of urinary tract infections for patients receiving dapagliflozin

[1]  Michael J Pencina,et al.  Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2007, Circulation.

[2]  Chari D Smith,et al.  Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. , 2005, Diabetes.

[3]  P. Norwood,et al.  A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers , 2009, Diabetes Care.

[4]  K. Khunti,et al.  Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis , 2016, Diabetes, obesity & metabolism.

[5]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[6]  H. Kaneto,et al.  Beneficial effects of sodium–glucose cotransporter 2 inhibitors for preservation of pancreatic β‐cell function and reduction of insulin resistance , 2016, Journal of diabetes.

[7]  P. Raskin.  Sodium–glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus , 2013, Diabetes/metabolism research and reviews.

[8]  K. Yoon,et al.  Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24‐week, double‐blind, placebo‐controlled trial , 2011, Diabetes, obesity & metabolism.

[9]  C. Kahn,et al.  Insulin signalling and the regulation of glucose and lipid metabolism , 2001, Nature.

[10]  K. Johnsson,et al.  Urinary tract infections in patients with diabetes treated with dapagliflozin. , 2013, Journal of diabetes and its complications.

[11]  S. Nisly,et al.  Canagliflozin, a new sodium-glucose cotransporter 2 inhibitor, in the treatment of diabetes. , 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  J. Rosenstock,et al.  Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy , 2012, Diabetes Care.

[13]  N. Iqbal,et al.  Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range , 2012, Diabetes, obesity & metabolism.

[14]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[15]  Yang Li,et al.  Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis , 2017, PeerJ.

[16]  G. Shulman,et al.  On Diabetes: Insulin Resistance Cellular Mechanisms of Insulin Resistance , 2022 .

[17]  S. Chrysant.  Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs. , 2017, Drugs of today.

[18]  S. Matthaei,et al.  Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes , 2015, Diabetes, obesity & metabolism.

[19]  V. Woo,et al.  Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[20]  T. Mansfield,et al.  Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial , 2013, BMC Medicine.

[21]  A. Kiyosue,et al.  Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double‐blind, placebo‐controlled trial , 2013, Diabetes, obesity & metabolism.

[22]  R. Henry,et al.  Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial , 2012, International journal of clinical practice.